{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dolutegravir+%2F+Lamivudine+%28DTG%2F3TC%29&page=2",
    "query": {
      "intervention": "Dolutegravir / Lamivudine (DTG/3TC)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 57,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dolutegravir+%2F+Lamivudine+%28DTG%2F3TC%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dolutegravir+%2F+Lamivudine+%28DTG%2F3TC%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T20:11:46.530Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01366547",
      "title": "Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir 50 mg",
          "type": "DRUG"
        },
        {
          "name": "abacavir 600 mg/lamivudine 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2011-06",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-08-08",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01366547"
    },
    {
      "nct_id": "NCT02831764",
      "title": "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine (3TC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 722,
      "start_date": "2016-07-18",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-12-07",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831764"
    },
    {
      "nct_id": "NCT02893488",
      "title": "Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "DTG/ABC/3TC FDC DISPERSIBLE TABLET",
          "type": "DRUG"
        },
        {
          "name": "EPZICOM (ABC/3TC)",
          "type": "DRUG"
        },
        {
          "name": "TIVICAY (DTG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-09-01",
      "completion_date": "2016-11-25",
      "has_results": false,
      "last_update_posted_date": "2017-08-04",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02893488"
    },
    {
      "nct_id": "NCT03332095",
      "title": "Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Doravirine (DOR)",
          "type": "DRUG"
        },
        {
          "name": "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral (ARV) medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 55,
      "start_date": "2018-07-02",
      "completion_date": "2022-05-25",
      "has_results": true,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332095"
    },
    {
      "nct_id": "NCT07202546",
      "title": "A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VH4524184",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir / Lamivudine (DTG/3TC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2026-02-11",
      "completion_date": "2028-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 34,
      "location_summary": "Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07202546"
    },
    {
      "nct_id": "NCT02384395",
      "title": "Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV",
        "Acute HIV Infection"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Abacavir 600 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-09",
      "completion_date": "2021-09-17",
      "has_results": true,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02384395"
    },
    {
      "nct_id": "NCT02831673",
      "title": "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine (3TC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 719,
      "start_date": "2016-07-21",
      "completion_date": "2022-08-15",
      "has_results": true,
      "last_update_posted_date": "2023-08-24",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831673"
    },
    {
      "nct_id": "NCT02263326",
      "title": "Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Continue current antiretroviral regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Babafemi Taiwo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2014-12",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2019-10-14",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02263326"
    },
    {
      "nct_id": "NCT02605954",
      "title": "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC",
          "type": "DRUG"
        },
        {
          "name": "Third Antiretroviral Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2015-11-18",
      "completion_date": "2018-01-24",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605954"
    },
    {
      "nct_id": "NCT04826562",
      "title": "Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir/Lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saint Michael's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-09-26",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-10-11T20:11:46.530Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04826562"
    }
  ]
}